Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 14/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 14/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26912645 | 0.89 | PDK2 (0.41) | PDK2ROCK2ROCK1ALDH1A1STING1 | |
| SCHEMBL26912304 | 0.81 | FEN1 (0.34) | ROCK2ROCK1ALDH1A1CGASFEN1 | |
| SCHEMBL26912975 | 0.73 | CGAS (0.40) | ROCK2ROCK1CGAS | |
| SCHEMBL26912403 | 0.72 | CGAS (0.36) | ROCK2ROCK1CGASFEN1 | |
| SCHEMBL26913392 | 0.71 | CGAS (0.37) | ROCK2ROCK1CGAS | |
| SCHEMBL26912534 | 0.71 | CGAS (0.39) | ROCK2ROCK1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL26912487 | 0.71 | CGAS (0.37) | ROCK2ROCK1CGASFEN1 | |
| SCHEMBL26912991 | 0.70 | CGAS (0.38) | ROCK2ROCK1CGAS | |
| SCHEMBL26913181 | 0.69 | CGAS (0.39) | ROCK2ROCK1CGASFEN1 | |
| SCHEMBL26913053 | 0.65 | CGAS (0.38) | ROCK2ROCK1CGASFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | PDK2 875/4885ROCK2 878/4885ROCK1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.